Investing.com -- Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds. The company’s shares are up over 3% premarket. The consumer health company posted adjusted earnings per share of $0.24, exceeding the analyst consensus of $0.23. Revenue for the quarter came in at $3.74 billion, topping expectations of $3.68 billion. Advertisement: High Yield Savings Offers Earn up to 4.35% APY** with $5k balance View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. Despite the earnings beat, Kenvue (NYSE:KVUE)’s stock dipped 0.9% following the release, suggesting a muted market reaction to the results. For the full year 2025, Kenvue now expects net sales growth of 1% to 3% year-over-year, including organic sales growth of 2% to 4% and a roughly 1% headwind from foreign currency translation. The company anticipates its adjusted operating income margin will decline compared to the previous year, reflecting the estimated impact of tariffs. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said CEO Thibaut Mongon. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." Kenvue’s first quarter net sales decreased 3.9% compared to the prior year period, with organic sales declining 1.2% and a 2.7% foreign currency headwind. The organic sales decline was attributed to a 0.3% unfavorable value realization due to planned strategic price investments and a 0.9% volume decline. The company’s gross profit margin expanded 40 basis points to 58.0%, while adjusted gross profit margin contracted 20 basis points to 60.0% compared to the same period last year. Kenvue also announced it had successfully completed its Transition Services Agreement exits in April, marking a significant milestone in its separation process. Related articles Kenvue’s Q2 earnings, revenue beat expectations Analysts turn more cautious on Coty Inc. Coinbase to expand its derivatives offering with $2.9B acquisition of Deribit View Comments
Kenvue’s Q2 earnings, revenue beat expectations
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...